Über den Autor

Dr. rer. nat. Mike Barbeck

University Hospital Hamburg-Eppendorf, Department of Oral and Maxillofacial Surgery, Laboratory for Regenerative Orofacial Medicine (LRM)
Martinistrasse 52
20246 Hamburg
040 7410 532 51


Personal Profile

Mike Barbeck has a 15 years experience in regenerative biomedical research working at institutes in Germany. He worked on the research on the principles of biomaterial-mediated tissue regeneration (bone substitute materials and collagen materials) resulting in 45 papers in peer-reviewed journals and an h-index of 15 (Web of Science). His research has led to further elucidation of cellular fundamentals of the foreign body response to different biomaterials with special focus on the role and differentiation of multinucleated giant cells for tissue regeneration.


  • 05/2013–11/2014 Gutenberg-University Mainz
    Cumulative doctorate
    Topic: „Evaluation of the tissue responses to biomaterial by means of histomorphometrical analysis methods with special focus on the involvement of multinucleated giant cells in the foreign body response (FBR)”
  • 04/2011–03/2013 Gutenberg-University Mainz
    M.Sc. Biology
  • 04/2009–03/2011 Gutenberg-University Mainz
    B.Sc. Biology
  • 04/2001–03/2009 Gutenberg-University Mainz
    Study of medicine

Work Experience

  • Since 01/2018 Senior researcher, Head of Tissue engineering research
    Section for Regenerative Orofacial Medicine
    Department of Oral & Maxillofacial Surgery
    University Medical Center Hamburg-Eppendorf
  • 07/2017–12/2017 Senior researcher
    Julius Wolff Institute and Center for Musculoskeletal Surgery
    Charité-Universitätsmedizin Berlin
  • Since 07/2016 Head of Research and Development
    Botiss biomaterials, Berlin
  • 10/2014–06/2016 Group leader in vivo research FORM-Lab (Frankfurt Orofacial Regenerative Medicine Lab)
    Department for Oral, Cranio-Maxillofacial and Facial Plastic Surgery
    Medical Center of the Goethe University Frankfurt
  • 03/2007–09/2014 Research assistant in vivo research
    Institute of Pathology
    Medical Center of the Gutenberg University Mainz

Relevant Publications

  • Barbeck M, Unger RE, Booms P, Dohle E, Sader RA, Kirkpatrick CJ, Ghanaati S. Monocyte preseeding leads to an increased implant bed vascularization of biphasic calcium phosphate bone substitutes via vessel maturation.J Biomed Mater Res A. 2016 Jul 15. PMID: 27419378
  • Barbeck M, Motta A, Migliaresi C, Sader R, Kirkpatrick CJ. Heterogeneity of biomaterial-induced multinucleated giant cells: Possible importance for the regeneration process?J Biomed Mater Res A. 2016 Feb;104(2):413-8. PMID: 26422451
  • Barbeck M, Najman S, Stojanović S, Mitić Ž, Živković JM, Choukroun J, Kovačević P, Sader R, Kirkpatrick CJ, Ghanaati S. Addition of blood to a phycogenic bone substitute leads to increased in vivo vascularization.Biomed Mater. 2015 Sep 11;10(5):055007. PMID: 26359820


D. Rimashevskiy, N. Zagorodniy, N. Batpenov, V. Alt, K. Glenske, S. Wenisch, S. Stojanovic, S. Najman, R. Smeets, D. Coraca-Huber, R. Schnettler

Antibiotic-loaded bone allografts for prophylaxis and treatment of bone infections



Every surgical procedure is accompanied by an immanent risk of bacterial infections. This matter needs to be especially considered in transplantations of bone allografts for regeneration of lost tissue in dental and orthopaedic applications, as the debridement is likely to result in worsening of the initial situation. One particular challenge is the population of bioimplant surfaces with biofilm forming bacteria which are less prone to antibiotic treatment [1].

The loading of bone allografts with antibiotic agents prior to implantation demonstrates a promising approach to overcome this issue and prevent bacterial infections. In the present study the pharmacokinetic properties of several antibiotics incorporated into allografts were analysed in vitro and in vivo. Furthermore, the in vivo biocompatibility of the antibiotic-loaded allografts were analysed.

Design and Methods

Freeze-dried bone allograft (FDBA) blocks (Cells+Tissuebank Austria, Krems (C+TBA), Austria) (Fig. 1 and 2) were rehydrated in antibiotic solutions of either Clindamycin, Gentamycin, Rifampicin, Vancomycin and a mixture of Vancomycin and Rifampicin for biofilm treatment for ten minutes in a 1:1 proportion prior to in vitro analyses or in vivo implantations. The in vitro concentration of remaining antibiotics was assessed every 24 hours with a total follow-up of ten days. For analysis of the in vivo release of the antibiotic-loaded were implanted using the femur implantation model in 30 rabbits (Fig. 3). The allografts were explanted at day one and three and the remaining amounts of the antibiotics were analysed using established microbiological methods. Furthermore, for analysis of the biocompatibility the antibiotic-loaded allografts were implanted into the proximal tibial bone and the initial tissue reactions were analysed up to seven days after implantation using established histological methods. 


Antibiotics are easily incorporated into FDBA blocks and steadily released from the bone material for a period of over ten days within the analysed time span. Especially within the first 24 hours high concentrations were released. Furthermore, the results of the in vivo study showed comparable results as a high release of the antibiotics was measured within the first three days. The second part of the in vivo study showed an excellent biocompatibility of all FDBA blocks combined with the different antibiotics.


The use of FDBA as carriers of antibiotic agents bares great potential in clinical application by eliminating systemic antibiotic-related side effects, minimising risks of antibiotic resistance formation, providing advantages for eukaryotic cells for faster surface population and consequently minimising the risk of surgical site infections and postoperative complications.

Bildergalerie (3)


  1. Stewart, Philip S., and J. William Costerton. „Antibiotic resistance of bacteria in biofilms.“ The lancet 358.9276 (2001): 135–138.